Inuvair Nexthaler

Beclometasone dipropionate and formoterol fumarate, the active ingredients in Inuvair Nexthaler, are an inhaled corticosteroid/long‑acting β2‑agonist combination presented as a dry powder inhaler for inhalation use. It provides maintenance therapy for asthma and chronic obstructive pulmonary disease in adult patients and is indicated for long‑term control of airway symptoms and to reduce the risk of exacerbations.

GNH USA supplies Inuvair Nexthaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU regulatory standards and is manufactured under GMP conditions.

Inuvair Nexthaler combines an inhaled corticosteroid and a long‑acting β2‑agonist to manage chronic airway diseases. - Asthma: reduces airway inflammation and provides sustained bronchodilation for long‑term symptom control. - Chronic obstructive pulmonary disease (COPD): improves lung function and decreases the frequency of exacerbations as maintenance therapy. - Bronchospasm: delivers rapid, lasting bronchodilation to relieve bronchial constriction during episodes.

Inhalation of Inuvair Nexthaler may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Throat irritation or soreness - Hoarseness or voice changes - Oral candidiasis (thrush) - Cough or wheezing after inhalation - Headache - Tremor or palpitations

Serious or Rare Side Effects: - Paradoxical bronchospasm - Severe allergic reactions (anaphylaxis, angioedema) - Adrenal suppression with prolonged high‑dose use - Cardiac arrhythmias - Pneumonia - Immunosuppression leading to opportunistic infections

Before prescribing Inuvair Nexthaler, clinicians should consider several precautionary measures to ensure safe use. - Monitor for oral thrush: rinse mouth with water and swallow after each inhalation. - Assess adrenal function: consider periodic evaluation in patients on long‑term high‑dose therapy. - Avoid use in patients with known hypersensitivity to beclometasone, formoterol, or any inhaler components. - Use the lowest effective dose to achieve control of symptoms. - Review concomitant β‑blocker therapy: may diminish bronchodilator response. - Store at room temperature below 25°C: keep in the original pack, protect from moisture.

Inuvair Nexthaler can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Non‑selective β‑blockers: may antagonize the bronchodilator effect of formoterol. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can increase systemic exposure to beclometasone. - Diuretics combined with high‑dose LABA: may heighten the risk of hypokalemia.

Moderate Interactions (Monitor Closely): - Theophylline: may have increased plasma concentrations when used with inhaled corticosteroids. - Ritonavir and other moderate CYP3A4 inhibitors: require monitoring of corticosteroid effects. - Live attenuated vaccines: inhaled corticosteroids may reduce vaccine efficacy; assess risk‑benefit.